Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
Patients with nonsquamous non–small cell lung cancer (nsNSCLC; largely lung adenocarcinoma) are at high risk of developing brain metastases. Preclinical data suggested that anti–VEGF-A therapy may prevent the formation of nsNSCLC brain metastases. Whether non-brain metastases are also prevented, and whether bevacizumab shows a brain metastases–preventive activity in cancer patients is unknown. Data of one nsNSCLC (stage IIIB/IV, AVAiL) and two breast cancer bevacizumab trials (HER2 negative, AVADO; HER2 positive, AVEREL) were retrospectively analyzed regarding the frequency of the brain versus other organs being the site of first relapse. For animal studies, the outgrowth of PC14-PE6 lung adenocarcinoma cells to brain macrometastases in mice was measured by intravital imaging: under control IgG (25 mg/kg) treatment, or varying doses of bevacizumab (25 mg/kg, 2.5 mg/kg, 0.25 mg/kg). Brain metastases as site of first relapse were significantly less frequent in the bevacizumab arm of the AVAiL trial (HR = 0.36, P < 0.001). In AVADO and AVEREL, no significant difference was seen. In mice, bevacizumab treatment led to secondary regressions of non-brain macrometastases, but did not reduce their total incidence, and did not improve survival. In a brain-seeking nsNSCLC metastasis model, treatment with bevacizumab inhibited brain metastases formation, which resulted in improved overall survival. In summary, bevacizumab has the potential to prevent brain metastases in nsNSCLC, but no preventive activity could be detected outside the brain. These data indicate that anti–VEGF-A agents might be particularly relevant for those stage III nsNSCLC patients who are at high risk to develop future brain metastases. Mol Cancer Ther; 15(4); 702–10. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting of VEGF with bevacizumab has been shown to reduce the incidence of brain metastasis in a mouse model of non-small-cell lung cancer (NSCLC), and when combined with carboplatin and paclitaxel, is associated with a reduced frequency of brain metastases as a site of first relapse in patients with this disease42”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Treatment with bevacizumab also delayed the incidence of brain metastases in a retrospective analysis [63].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Self-citationProphylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Aupérin, A., Arriagada, R., Pignon, J.-P., Le Péchoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,718 · cited 1×
“In case of small-cell lung cancer, prophylactic cranial radiotherapy (pWBRT) of patients resulted in a prolongation of brain metastases-free and overall survival (35), whereas a clear survival benefit was not seen in NSCLC (36).”
BackgroundReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505 · cited 2×
“However, the current clinical benefits achieved by bevacizumab, which is administered primarily to nsNSCLC patients with metastatic disease and high existing tumor burden (16), are modest at best (15, 17).”
BackgroundSelf-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · cited 3×
“In control animals, a thickened and abnormal vascular wall identified by collagen IV staining (26) was observed where metastatic tumor cells coopted the perivascular niche, which was regularly found in micro- and macrometastases (Fig.”
BackgroundMethodSelf-citationReal-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
Self-citationMiles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Self-citationReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638
Self-citationSoffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636 · cited 3×
“In case of small-cell lung cancer, prophylactic cranial radiotherapy (pWBRT) of patients resulted in a prolongation of brain metastases-free and overall survival (35), whereas a clear survival benefit was not seen in NSCLC (36).”
BackgroundCameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Cited by
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
“Treatment with bevacizumab also delayed the incidence of brain metastases in a retrospective analysis [63].”
BackgroundSelf-citationEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Functional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
“Of interest, a recent meta-analysis of clinical trials provided evidence that VEGF-inhibition is associated with fewer brain metastases in patients diagnosed with adenocarcinomas of the lung [54].”
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
Saito, H., Fukuhara, T., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30035-x · Cited by 615
Metadata
- Authors
- Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., von Baumgarten, L., Preusser, M., Wick, W., & Winkler, F.
- Affiliations
- 1Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- German Cancer Research Center (DE)
- German Center for Lung Research (DE)
- Mount Vernon Cancer Centre (GB)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- IRCCS Ospedale San Raffaele (IT)
- F. Hoffmann-La Roche AG (CH)
- 10DASTA GmbH, Heddesheim, Germany.
- University of Bergen (NO)
- 12Department of Neurology, Ludwig-Maximilians University Hospital, Munich, Germany.
- Comprehensive Cancer Center Vienna (AT)
- Corresponding author
- Winkler, Frank
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-04-01
- Volume
- 15
- Issue
- 4
- Pages
- 702-710
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2302258098
- Cited by
- 119
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 6 · 2016: 8
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- bevacizumab, brain metastases, lung adenocarcinoma, non-small cell lung cancer, metastasis prevention, intravital imaging, breast cancer, overall survival
- MeSH terms
- Bevacizumab, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Brain Neoplasms, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Neoplasm Staging, Neovascularization, Pathologic, Retrospective Studies, Multicenter Studies as Topic, Incidence, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Angiogenesis Inhibitors, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0582
- The paper
- Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., von Baumgarten, L., Preusser, M., Wick, W., & Winkler, F. (2016). Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.